Merck (MRK) initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX(TM) (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC

Merck's initiation of the Phase 3 KANDLELIT-007 trial for Calderasib, in combination with KEYTRUDA, is a significant step in advancing its oncology pipeline.

Newsquawk StaffPublished On the live feed at 4 more headlines followed before this page went public
Newsquawk headlinesUTC

Warner Bros Discovery (WBD) says board deems Paramount Skydance (PSKY) offer inadequate due to insufficient value and risks

US MBA 30-Year Mortgage Rate (Jan/02) 6.32% (Prev. 6.31%)

Merck (MRK) initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX(TM) (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC

KKR to invest USD 1.5bln in its European data centre business, FT reports

HSBC raises silver price forecast to USD 68.25/oz in 2026, and USD 57.00/oz in 2027

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This combination therapy could enhance treatment options for patients with advanced non-small cell lung cancer (NSCLC), potentially influencing the competitive landscape in cancer therapies and impacting Merck's valuation if positive results emerge.

Related headlines

The whole workspace, free to try.

Try it free